HC Wainwright Forecasts Higher Earnings for Spyglass Pharma

Spyglass Pharma, Inc. (NASDAQ:SGP) – Analysts at HC Wainwright raised their Q2 2026 earnings estimates for Spyglass Pharma in a note issued to investors on Monday, March 30th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.47) per share for the quarter, up from their previous forecast of ($0.49). HC Wainwright currently has a “Buy” rating and a $37.00 price objective on the stock. HC Wainwright also issued estimates for Spyglass Pharma’s Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.48) EPS and FY2026 earnings at ($2.16) EPS.

Spyglass Pharma (NASDAQ:SGP) last announced its quarterly earnings data on Thursday, March 26th. The company reported ($5.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.61) by $0.89.

SGP has been the subject of several other research reports. Zacks Research upgraded Spyglass Pharma to a “hold” rating in a research note on Wednesday, March 4th. Leerink Partners lowered shares of Spyglass Pharma to a “market perform” rating in a research note on Tuesday, March 3rd. Citigroup started coverage on shares of Spyglass Pharma in a report on Tuesday, March 3rd. They issued a “buy” rating and a $42.00 target price on the stock. Jefferies Financial Group began coverage on shares of Spyglass Pharma in a research note on Tuesday, March 3rd. They issued a “buy” rating and a $62.00 price target for the company. Finally, Wall Street Zen downgraded shares of Spyglass Pharma from a “hold” rating to a “sell” rating in a research report on Saturday. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $45.00.

Spyglass Pharma Trading Up 10.9%

Shares of NASDAQ SGP opened at $25.91 on Wednesday. Spyglass Pharma has a 1-year low of $20.16 and a 1-year high of $32.44.

Insider Transactions at Spyglass Pharma

In other Spyglass Pharma news, Director Ra Capital Management, L.P. acquired 3,690,000 shares of the stock in a transaction dated Monday, February 9th. The stock was acquired at an average cost of $16.00 per share, with a total value of $59,040,000.00. Following the transaction, the director owned 5,966,439 shares in the company, valued at $95,463,024. The trade was a 162.10% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

About Spyglass Pharma

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).